Ascentage Pharma
AAPG
12 hedge funds and large institutions have $3.22M invested in Ascentage Pharma in 2025 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
100% more funds holding
Funds holding: 6 → 12 (+6)
0.18% less ownership
Funds ownership: 0.27% → 0.09% (-0.18%)
38% less capital invested
Capital invested by funds: $5.21M → $3.22M (-$1.99M)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NIM
NEOS Investment Management
Westport,
Connecticut
|
+$408K |
| 2 |
TE
Tema ETFs
New York
|
+$408K |
| 3 |
HSBC Holdings
London,
United Kingdom
|
+$262K |
| 4 |
Chevy Chase Trust
Bethesda,
Maryland
|
+$152K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$129K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$3.51M |
| 2 |
XC
XY Capital
Central,
Hong Kong
|
-$472K |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
-$350K |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$218K |
| 5 |
PD
Point72 (DIFC)
Dubai,
United Arab Emirates
|
-$119K |
AAPG Hedge Fund Activity: Q2 2025 in Review
12 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Ascentage Pharma (AAPG) for Q2 2025, worth a combined $3.22M — down 38% from $5.21M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new AAPG positions and 3 closed out — a net gain of 6 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was NEOS Investment Management, opening a new position worth an estimated $408K. The largest seller was Monashee Investment Management, exiting entirely with an estimated $3.51M sold.
- 12 institutional investors held Ascentage Pharma (AAPG) as of Q2 2025, up from 6 in Q1 2025.
- Funds reported $3.22M of Ascentage Pharma stock for Q2 2025, down 38% quarter-over-quarter.
- 9 funds opened new Ascentage Pharma positions in Q2 2025 and 3 closed out, a net change of +6 holders.
- The largest Ascentage Pharma buyer in Q2 2025 was NEOS Investment Management, an estimated $408K added.
- The largest Ascentage Pharma seller in Q2 2025 was Monashee Investment Management, an estimated $3.51M sold.
Based on aggregated 13F filings for Q2 2025.